Fosifloxuridine-nafalbenamide-NUC-3373-DataSheet-生命科學試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEFosifloxuridinenafalbenamideCat.No.:HY-109115CASNo.:1332837-31-6Synonyms:NUC-3373分?式:C??H??FN?O?P分?量:613.53作?靶點:ThymidylateSynthase作?通路:Apoptosis儲存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實驗DMSO:100mg/mL(162.99mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM1.6299mL8.1496mL16.2991mL5mM0.3260mL1.6299mL3.2598mL10mM0.1630mL0.8150mL1.6299mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；?旦配成溶液，請分裝保存，避免反復凍融造成的產(chǎn)品失效。儲備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲存時，請在6個?內(nèi)使?，-20°C儲存時，請在1個?內(nèi)使?。體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%saline1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemESolubility:≥2.5mg/mL(4.07mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.5mg/mL(4.07mM);Clearsolution3.請依序添加每種溶劑：10%DMSO>>90%cornoilSolubility:≥2.5mg/mL(4.07mM);ClearsolutionBIOLOGICALACTIVITY?物活性Fosifloxuridinenafalbenamide(NUC-3373)屬于嘧啶核苷酸類似物，?種胸腺嘧啶合酶(Thymidylatesynthase)抑制劑。Fosifloxuridinenafalbenamide具有抗癌活性。Fosifloxuridinenafalbenamide具有誘發(fā)宿主免疫反應和增強免疫治療的潛?[1][2]。體外研究Fosifloxuridinenafalbenamideinducesthereleaseofdamage-associatedmolecularpatterns(DAMPs),withincreasedexpressionofcalreticulin(CRT)atthecellsurfaceandconcomitantlossofnuclearnuclearhighmobilitygroupboxprotein1(HMGB1)[1].體內(nèi)研究Fosifloxuridinenafalbenamideexhibitsanti-canceractivityinHT-29nudemousexenograftmodels[2].REFERENCES[1].FionaG.McKissock,etal.Abstract1848:NUC-3373inducesERstressandthereleaseofdamageassociatedmolecularpatternsincolorectalcancercells.CancerResAugust152020(80)(16Supplement)1848.[2].EssamA.Ghazaly,etal.AbstractB46:NUC-3373:Anovelpyrimidinenucleotideanaloguethatovercomeskeycancerdrugresistancelimitingpatientsurvival.MolCancerTherDecember12015(14)(12Supplement2)B46.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuse